NCT06330064 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06330064
Title	A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Acronym	IDeate-PanTumor02
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Daiichi Sankyo
Indications	gastric adenocarcinoma endometrial cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma esophagus adenocarcinoma hepatocellular carcinoma transitional cell carcinoma colorectal cancer pancreatic ductal adenocarcinoma lung non-squamous non-small cell carcinoma
Therapies	Ifinatamab deruxtecan
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NLD \| ITA \| IRL \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS \| ARG

No variant requirements are available.